RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$904M
1-Year Est. Return
12.31%
1 Year Est. Return
+12.31%
AUM
$904M
AUM Growth
+$113M
(+14%)
Holding
103
Top Buys
| 1 | +$14.1M | |
| 2 | +$13.9M | |
| 3 | +$11.1M | |
| 4 |
Axsome Therapeutics
AXSM
|
+$9.96M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$9.17M |
Top Sells
| 1 | +$15.8M | |
| 2 | +$13.9M | |
| 3 | +$11.4M | |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$10.1M |
| 5 |
Gilead Sciences
GILD
|
+$9.77M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Boston Scientific
BSX
$137B
| $42.8M | 4.73% |
438,000
+142,000
|
|
||
2
Eli Lilly
LLY
$953B
| $40.8M | 4.51% |
53,420
-4,450
|
|
||
3
AbbVie
ABBV
$388B
| $30.2M | 3.34% |
130,375
+61,000
|
|
||
4
Danaher
DHR
$166B
| $26.7M | 2.95% |
134,452
+13,000
|
|
||
5
Alignment Healthcare
ALHC
$4.76B
| $25.8M | 2.86% |
1,479,284
+192,000
|
|
||
6
Intuitive Surgical
ISRG
$186B
| $21.7M | 2.4% |
48,500
+4,150
|
|
||
7
UnitedHealth
UNH
$323B
| $21.6M | 2.39% |
62,530
+32,100
|
|
||
|
8
Axsome Therapeutics
AXSM
$9.37B
| $21M | 2.32% |
172,800
+82,000
|
|
||
9
CVS Health
CVS
$105B
| $20.9M | 2.31% |
277,362
-18,000
|
|
||
10
McKesson
MCK
$101B
| $20.5M | 2.27% |
26,600
-1,117
|
|
||
11
Regeneron Pharmaceuticals
REGN
$79.2B
| $20.3M | 2.25% |
36,100
+8,400
|
|
||
12
Ionis Pharmaceuticals
IONS
$13B
| $20.3M | 2.24% |
310,000
+128,000
|
|
||
13
Medtronic
MDT
$129B
| $19.5M | 2.16% |
205,000
+25,500
|
|
||
14
Cencora
COR
$68.6B
| $19.5M | 2.16% |
62,375
+13,000
|
|
||
15
Exact Sciences
EXAS
$19.4B
| $19M | 2.11% |
348,000
-2,000
|
|
||
16
Insmed
INSM
$33.3B
| $19M | 2.1% |
131,885
-43,550
|
|
||
17
Glaukos
GKOS
$6.89B
| $18.8M | 2.08% |
230,000
-5,000
|
|
||
18
Vertex Pharmaceuticals
VRTX
$119B
| $18.4M | 2.04% |
46,955
-14,500
|
|
||
19
Insulet
PODD
$19.1B
| $17.9M | 1.98% |
58,000
+12,000
|
|
||
20
Cooper Companies
COO
$15.9B
| $16.2M | 1.8% |
237,000
+67,000
|
|
||
21
Neurocrine Biosciences
NBIX
$13.6B
| $16.1M | 1.78% |
114,717
-34,500
|
|
||
22
Encompass Health
EHC
$9.9B
| $15.2M | 1.68% |
119,400
-17,000
|
|
||
23
Cardinal Health
CAH
$49.5B
| $14.8M | 1.63% |
94,000
+39,000
|
|
||
|
24
Thermo Fisher Scientific
TMO
$235B
| $14.6M | 1.61% |
30,040
+18,900
|
|
||
25
Alnylam Pharmaceuticals
ALNY
$47.3B
| $14.5M | 1.61% |
31,875
-19,322
|
|